Drugs / HTX-011A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02762929 | May 2016 → Feb 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02689258 | Feb 2016 → Mar 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02504580 | Jul 2015 → Mar 2017 | — | Heron Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HTX-011A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02689258 ↗ |
| Known as | HTX-011-49 | “HTX-011A is the second formulation studied (HTX-011-49).” NCT02689258 ↗2“HTX-011A is the second formulation studied (HTX-011-49).” NCT02762929 ↗ “HTX-011A is the second formulation studied (HTX-011-49).” NCT02504580 ↗ |
| Route | Other | “HTX-011A (bupivacaine/meloxicam) by injection.” NCT02504580 ↗ |